ENO2 and androgen insensitivity syndrome: For the 3-month prognosis of AIS patients, serum NSE (on admission) level of 17.05 μg/L provided the best sensitivity (65.38%) and specificity (40.35%) according to the ROC curve, with an AUC of 0.585 (95% CI, 0.529–0.662; P = 0.003).